clinical trial · NCT04984811
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech·phase2·active not recruiting·n = 83
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNon-Small Cell Lung CarcinomaNonsmall Cell Lung CancerNon Small Cell Lung Cancerefineptakin alfaAtezolizumab
brief summary
This is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable disease according to RECIST 1.1. This Phase II study will enroll up to 83 subjects.
started
Nov 3, 2021
primary completion
Sep 1, 2024
completion
Mar 1, 2025
last updated
Mar 5, 2024
official title
A Multicenter, Open-label, Single-arm Phase II Study to Evaluate Anti-tumor Efficacy and Safety of NT-I7 in Combination With Atezolizumab in Subjects With Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol